Anti-inflammatory Effects of Abdominal Vagus Nerve Stimulation on Experimental Intestinal Inflammation.
Sophie C Payne, John B Furness, Owen Burns...
https://pubmed.ncbi.nlm.nih.gov/31133776/Actively Recruiting
Led by The Bionics Institute of Australia · Updated on 2026-10-02
5
Participants Needed
3
Research Sites
221 weeks
Total Duration
Researchers are evaluating the safety of abdominal vagus nerve stimulation aVNS for adults with moderate to severe rheumatoid arthritis RA that has not improved with medication. This open-label study focuses on adult-onset RA patients who have drug-refractory symptoms. The goal is to assess safety, device performance, and any potential benefits of the aVNS device over time. Participants will have the aVNS device implanted through keyhole surgery. Starting two weeks after implantation, stimulation will be delivered daily for about 3 hours per day over a 22-week period. The device is controlled by the participant using a controller to switch it on and off. After this initial phase, participants may continue using the device, which will stay implanted unless removal is clinically needed or requested by the participant. Throughout the study, participants will undergo clinical assessments of RA symptoms and device performance at 2, 6, 12, and 24 weeks post-surgery. Following the initial treatment phase, participants will be monitored twice yearly for up to 5 years to track safety and device effects. Total participation in the trial lasts about 5 years, including follow-up monitoring and evaluations.
CONDITIONS
The Reboot Study: A Safety Study of Abdominal Vagus Nerve Stimulation for Moderate to Severe Drug Refractory Rheumatoid Arthritis
A
A/Prof Shereen Oon, MBBS, PhD
A
Angela Chia, RN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Bionics Institute of Australia
Lead Sponsor
St Vincent's Hospital Melbourne
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 to 24 weeks
Participants undergo laparoscopic surgery to implant the abdominal vagus nerve stimulation device. Starting two weeks after surgery, they use the device daily for about 3 hours a day over 22 weeks, controlling it with a handheld controller.
Visits at 2, 6, 12, and 24 weeks post-surgery
Duration - Up to 5 years
Participants who complete the initial treatment phase are monitored twice yearly for up to 5 years to assess safety and device performance. The device remains implanted unless removal is needed or requested.
Twice yearly visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DEVICE_FEASIBILITY
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Sophie C Payne, John B Furness, Owen Burns...
https://pubmed.ncbi.nlm.nih.gov/31133776/Sophie C Payne, John B Furness, Martin J Stebbing
https://pubmed.ncbi.nlm.nih.gov/30390018/Sophie C Payne, Evange Romas, Tomoko Hyakumura...
https://pubmed.ncbi.nlm.nih.gov/36478876/The Bionics Institute of Australia
Lead Sponsor
St Vincent's Hospital Melbourne
Collaborating Sponsor